Research and Development

As a premium e-liquid manufacturer, we invest heavily into research and development with concentrated efforts in three main areas: product development, testing, and tobacco harm reduction. We are passionate about the industry not only because our employees vape, but because the owners are also avid vapers who know the importance of consistent, safe, and quality products.

Product Development

We have a robust product development pipeline with direct involvement from the company’s founders and extensive participation from company employees. We are passionate about our products and develop and test our flavors under the guidance of third parties with demonstrated track records in the flavor and FDA-regulated industries. In addition, these consultants and suppliers have a comprehensive understanding of the specific issues surrounding the inhalation of products containing nicotine.

Much of our work is also consumer-driven. We listen to our consumers and respond to their demands. More innovations are soon to come.

Future developments will be influenced by consumer expectations and FDA and EU regulatory developments, leveraging our experts’ background in FDA-regulated tobacco products.


Testing is a crucial element of our quality control and product innovation. We conduct routine in-house testing of incoming products and materials, and use outside labs as needed to comply with quality and regulatory requirements. Several of our staff and consultants have advanced science degrees and stay up to date with industry and scientific developments.

All of our e-liquids on the market have been independently tested via high-performance liquid chromatography (HPLC) and nuclear magnetic resonance spectroscopy (NMR).

Tobacco Harm Reduction

While we do not market products with therapeutic or modified risk indications, our efforts in research and development, as well as compliance, support global tobacco harm reduction. We acknowledge the progressive approach of the U.K. National Institute for Health and Care Excellence (NICE), which, in its Smoking: Tobacco Harm Reduction Guidance recommends that doctors inform patients of the availability of non-medicinal vaping products and that these are likely to be less harmful than cigarettes. We are also encouraged by the Public Health England Report on electronic cigarettes, and by recent Public Health England statements that quantified electronic cigarettes as being 95 percent less harmful than conventional cigarettes.

“E-cigarettes are not completely risk-free,” said Kevin Fenton, the director of health and well-being at Public Health England.  “But when compared to smoking, evidence shows they carry just a fraction of the harm.”

Much more research, however, is required to understand the long-term impact of the use of vaping and its full harm reduction potential. KONTAM VAPE is open to collaboration with academia and research organizations in furtherance of such research.